摘要
目的探讨短期雾化吸入布地奈德混悬液治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者的疗效分析。方法 78例AECOPD患者被随机分为吸入激素组(27例)、全身激素组(25例)和对照组(26例)。三组均给予吸氧、抗感染、爱全乐雾化吸入扩张支气管及止咳化痰等常规治疗。吸入激素组加用布地奈德混悬液2 mg(2次/d),氧气雾化吸入。全身激素组在常规治疗的基础上加用泼尼松龙40 mg(1次/d),静脉给药。三组均于治疗前及治疗7 d后测定肺功能、动脉血气及空腹血糖。结果治疗前,三组间各指标比较无明显差异。治疗后,三组肺功能及动脉血气较治疗前均有明显改善(P均<0.05);吸入激素组与全身激素组比较,除血糖外(P<0.05),各指标差异无统计学意义(P>0.05);吸入激素组与对照组比较,肺功能、血气指标差异有统计学意义(P<0.05),血糖比较差异无统计学意义(P>0.05)。结论雾化吸入布地奈德混悬液治疗AECOPD临床疗效确切,与全身应用糖皮质激素相比,全身副作用少,安全性高。
Objective To discuss the curative effect of inhaling budesonide in the treatment of acute exacerbations of chronic obstructive pulmonary disease（AECOPD）. Methods From December 2010 to May 2012, 78 patients with AECOPD were randomly divided into three groups（inhalation group 27cases, IV injection group 25 cases and control group 26 cases）.The patients in control group were treated with standard therapy only the patients in inhalation group attached to inhaling budesonide suspension with oxygen, and those in IV injection group were treated with both standard therapy and IV injection prednisolone.All the patients underwent pulmonary function test, arterial blood gas analysis, and blood glucose respectively at entry and seven days after therapy. Results There were significant improvement of all pulmonary function and arterial blood gas relevant parameters among three groups after therapy（P0.05）than those of IV injection group except blood glucose（P0.05）. Conclusion Budesonide inhalation is an effective and safe treatment for AECOPD patients.
出处
《中国现代药物应用》
2014年第11期38-40,共3页
Chinese Journal of Modern Drug Application
关键词
慢性阻塞性肺疾病
急性加重期
布地奈德
雾化吸入
Chronic obstructive pulmonary disease
Acute exacerbations
Budesonide
Inhalation
